Kreis Leslie W.

Average Profitability
<0.0001%
Insider Buys Quantity
5
Insider Buys Sum
$2.18M
Insider Sells Quantity
8
Insider Sells Sum
$3.15M

Insider Activity of Kreis Leslie W.

According to the SEC Form 4 filings, Kreis Leslie W., being in a position of

  1. 10 percent owner at Lantern Pharma Inc.,
    оver the last 12 months, has bought 0 shares, and sold 232889 shares for $1.11M,
    over all time since 2022-11-08, has bought 0 shares, and sold 728237 shares for $3.15M.

The largest purchase of all time was on 2022-11-15 and amounted to 1500000 shares of Cognition Therapeutics, Inc. for $1.8M.

The largest sale of all time was on 2022-11-08 and amounted to 350000 shares of Lantern Pharma Inc. for $1.54M.

Biography of Kreis Leslie W.

No biography is available at this moment.

2024-05-24SaleLantern Pharma Inc.
LTRN
10 percent owner
20,000
0.1889%
$6.33$126,600-39.23%
2024-05-23SaleLantern Pharma Inc.
LTRN
10 percent owner
10,000
0.0932%
$6.25$62,500-37.38%
2024-02-29SaleLantern Pharma Inc.
LTRN
10 percent owner
19,703
0.1653%
$4.87$95,954-7.69%
2024-02-28SaleLantern Pharma Inc.
LTRN
10 percent owner
74,297
0.6556%
$4.85$360,340-12.84%
2024-02-27SaleLantern Pharma Inc.
LTRN
10 percent owner
50,000
0.4668%
$4.40$220,000-1.11%
2024-01-17SaleLantern Pharma Inc.
LTRN
10 percent owner
58,889
0.6101%
$4.20$247,334+10.76%
2023-11-29SaleLantern Pharma Inc.
LTRN
10 percent owner
145,348
1.1501%
$3.44$499,997+7.42%
2023-06-21PurchaseAzitra, Inc.
AZTR
10 percent owner
2.3M
$3.15$7.24M-73.83%
2022-12-12PurchaseIN8bio, Inc.
INAB
director
75,001
0.359%
$2.48$185,912-44.94%
2022-11-28PurchaseCognition Therapeutics, Inc.
CGTX
director
16,064
0.0706%
$2.65$42,565-31.76%
2022-11-16PurchaseCognition Therapeutics, Inc.
CGTX
director
71,000
0.3069%
$1.40$99,400+27.37%
2022-11-15PurchaseCognition Therapeutics, Inc.
CGTX
director
1.5M
5.2511%
$1.20$1.8M+20.34%
2022-11-08SaleLantern Pharma Inc.
LTRN
director
350,000
3.233%
$4.40$1.54M+13.9%
2022-09-28PurchaseIN8bio, Inc.
INAB
25,000
0.1111%
$2.02$50,535-18.57%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.